The new rules are intended to bridge the gap between the DEA’s current PHE waivers and a post-PHE telehealth environment, according to a Feb. 24 release from the DEA.
Four things to know:
- The new rules would provide safeguards for telemedicine consultations conducted by a medical practitioner that has never met with a patient in-person and controlled substance prescribing via telemedicine.
- The new rules would allow practitioners to prescribe a 30-day supply of Schedule III-V non-narcotic controlled medications via telemedicine.
- The new rules would also allow practitioners to prescribe a 30-day supply of buprenorphine for the treatment of opioid use disorder via telemedicine.
- These new rules would allow clinicians to prescribe these substances without an in-person evaluation or referral from a medical practitioner, as long as the prescription is consistent with federal and state laws.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.